A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome. Issue 1 (January 2016)

• Record Type: Journal Article
• Authors: Mhao, Noorhan S.; Al-Hilli, Ahmed S.A.; Hadi, Najah R.; Jamil, Dina A.; Al-Aubaidy, Hayder A.
• Is Part Of: Diabetes & metabolic syndrome. Volume 10:Issue 1(2016)Supplement 1
• Page Start: S95
• Page End: S98
• Publication Date: 2016-01
• Subjects: Ethinyl estradiol-cyproterone acetate -- Metformin -- Metabolic regulation -- Polycystic ovarian syndrome; Diabetes -- Periodicals; Metabolism -- Disorders -- Periodicals; Diabetes Mellitus -- Periodicals; Metabolic Diseases -- Periodicals; Diabète -- Périodiques; Métabolisme, Troubles du -- Périodiques; Endocrinologie -- Périodiques; Diabète -- Physiopathologie -- Périodiques; Diabetes; Metabolism -- Disorders; Electronic journals; Periodicals; 616.462
• DOI: 10.1016/j.dsx.2015.10.001
• Languages: English
• ISSNs: 1871-4021

Abstract

Abstract: Aim: This study was done to illustrate the clinical and biochemical effects of ethinyl estradiol-cyproterone acetate (EE-AC) and metformin in this disease. Methods: This was a randomized control trial study, done on twenty-six female patients already diagnosed as cases of PCOS. Participants were divided into two study groups: group one (Group 1), received metformin of 500 mg twice daily and the second group (Group 2), was given ethinyl estradiol–cyproterone acetate for 21 consecutive days followed by 7 days drug-free. The course of the treatment for both groups was continued for three consecutive months. Results: Group 1 showed a statistical significant increase in serum high density lipoprotein cholesterol (HDL-C) levels ( P = 0.006) and a decrease in the level of triglyceride (TG) ( P = 0.006). In addition, Group 1 had a significant reduction in the levels of very density lipoprotein cholesterol (VLDL-C) ( P = 0.006). Group 2 had a significant increase in serum TG levels ( P = 0.01), associated with a significant decrease in serum LDL-C ( P = 0.04). Serum testosterone was significantly reduced in group 1 ( P = 0.038). This was associated with an improvement in glucose tolerance test (GTT) and BMI in the same group (group 1). Group 2, had an improvement in the menstrual cycle control; hirsutism and acne. Conclusion: This study showed that metformin treatment is beneficial in improving serum lipids; glucose homeostasis and BMI, however, the ethinyl estradiol-cyproterone acetate is superior in improving the clinical manifestation of patients with PCOS, including menstrual cycle regulation, hyperandrogenic state.